Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Assets (2016 - 2025)

Altimmune (ALT) has disclosed Current Assets for 16 consecutive years, with $278.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 102.68% to $278.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $278.2 million through Dec 2025, up 102.68% year-over-year, with the annual reading at $278.2 million for FY2025, 102.68% up from the prior year.
  • Current Assets for Q4 2025 was $278.2 million at Altimmune, up from $216.6 million in the prior quarter.
  • The five-year high for Current Assets was $278.2 million in Q4 2025, with the low at $137.3 million in Q4 2024.
  • Average Current Assets over 5 years is $194.1 million, with a median of $192.0 million recorded in 2022.
  • The sharpest move saw Current Assets skyrocketed 518.59% in 2021, then tumbled 34.52% in 2024.
  • Over 5 years, Current Assets stood at $204.1 million in 2021, then fell by 5.54% to $192.8 million in 2022, then grew by 8.72% to $209.6 million in 2023, then crashed by 34.52% to $137.3 million in 2024, then surged by 102.68% to $278.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $278.2 million, $216.6 million, and $188.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.